etrasimod vs tamuzimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
etrasimod · Velsipity
Marketed by Pfizer and partners
NCT03945188 · Phase 3 · completed
Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.
Next expected readout: June 2027 · NCT07782242 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Clinical Remission at Week 12; Percentage of Participants Achieving Clinical Remission at Week 52: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) (met)
Result source: NCT03945188
tamuzimod
Developed by Eli Lilly and partners
NCT05156125 · Phase 2 · terminated
This was a randomized, quadruple-blind, placebo-controlled trial in 213 patients using clinical remission on the modified Mayo score, a validated disease-activity measure combining symptoms and endoscopy, as the primary endpoint. Both the 60 mg and 30 mg tamuzimod doses achieved significantly higher remission rates than placebo at week 13.
Reported efficacy
Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): Clinical Remission at 13 Weeks (Day 1 of Induction treatment period to Week 13): VTX002 60 mg Once Daily 19/68 (27.9%) | VTX002 30 mg Once Daily 17/71 (23.9%) vs Placebo Once Daily 8/70 (11.4%) (met)
Result source: NCT05156125
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | etrasimod | tamuzimod |
|---|---|---|
| Clinical remission (induction) | 27% vs 7.4%+19.6 vs placeboNCT039451886 other results
| 27.9% vs 11.4%+16.5 vs placeboNCT051561251 other result
|
| Clinical remission (maintenance) | 32.1% vs 6.7%+25.4 vs placeboNCT039451883 other results
| —Not reported |
| Clinical response (induction) | 62.4% vs 34.1%+28.3 vs placeboNCT039451886 other results
| —Not reported |
| Endoscopic improvement (induction) | 35% vs 14.1%+20.9 vs placeboNCT039451886 other results
| —Not reported |
| Corticosteroid-free remission (maintenance) | 32.1% vs 6.7%+25.4 vs placeboNCT039451886 other results
| —Not reported |
Clinical remission (induction)
- etrasimod
- 27% vs 7.4%+19.6 vs placeboNCT03945188
6 other results
- 24.8% vs 15.2% NCT03996369
- 26.3% vs 0% NCT05061446
- 6.7% vs 0% NCT05061446
- 33% vs 8.1% NCT02447302
- 16% vs 8.1% NCT02447302
- 28.3% vs 11.7% NCT04607837
- tamuzimod
- 27.9% vs 11.4%+16.5 vs placeboNCT05156125
1 other result
- 23.9% vs 11.4% NCT05156125
Clinical remission (maintenance)
- etrasimod
- 32.1% vs 6.7%+25.4 vs placeboNCT03945188
3 other results
- 25% vs 7.1% NCT04706793
- 49.1% vs 17.4% NCT03945188
- 26% vs 18.3% NCT04607837
- tamuzimod
- —Not reported
Clinical response (induction)
- etrasimod
- 62.4% vs 34.1%+28.3 vs placeboNCT03945188
6 other results
- 62.2% vs 41.1% NCT03996369
- 50.6% vs 32.5% NCT02447302
- 43.7% vs 32.5% NCT02447302
- 55.9% vs 36.7% NCT04607837
- 52.6% vs 7.1% NCT05061446
- 33.3% vs 7.1% NCT05061446
- tamuzimod
- —Not reported
Endoscopic improvement (induction)
- etrasimod
- 35% vs 14.1%+20.9 vs placeboNCT03945188
6 other results
- 30.6% vs 18.8% NCT03996369
- 41.8% vs 17.8% NCT02447302
- 22.5% vs 17.8% NCT02447302
- 44.1% vs 20% NCT04607837
- 26.3% vs 0% NCT05061446
- 6.7% vs 0% NCT05061446
- tamuzimod
- —Not reported
Corticosteroid-free remission (maintenance)
- etrasimod
- 32.1% vs 6.7%+25.4 vs placeboNCT03945188
6 other results
- 31% vs 7.5% NCT03945188
- 25% vs 7.1% NCT04706793
- 25.2% vs 16.7% NCT04607837
- 25.2% vs 16.7% NCT04607837
- 16.2% vs 16.7% NCT04607837
- 30% vs 30% NCT04607837
- tamuzimod
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. etrasimod: 5 of 5 rows · tamuzimod: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | etrasimod | tamuzimod |
|---|---|---|
| Symptomatic Remission responder rate · % of participants Induction | 43.1% (n=274) vs 21.5% (n=135) placebo @ 16wk2 mga,b,c NCT03945188 · Phase 3 · monotherapy | 42.6% (n=68) vs 25.7% (n=70) placebo @ 13wk*60 mg once dailyd,a,b,c NCT05156125 · Phase 2 · monotherapy · converted to % from 29 Participants as posted show 1 more dose40.8% (n=71) vs 25.7% (n=70) placebo @ 13wk*30 mg once daily NCT05156125 · Phase 2 · monotherapy · converted to % from 29 Participants as posted |
| Dropout rate | 44.3%2 mge NCT03945188 · Phase 3 · monotherapy show 8 more results10.5%2 mg NCT03996369 · Phase 3 · monotherapy 35.7%2 mg NCT04706793 · Phase 3 · monotherapy 37.4% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 5.9%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 17.9%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 8%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 9.6%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence | 4.3%60 mg once dailye NCT05156125 · Phase 2 · monotherapy show 6 more results—60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy 4.1%30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Discontinued due to AEs | 3.5%2 mge NCT03945188 · Phase 3 · monotherapy show 8 more results3.8%2 mg NCT03996369 · Phase 3 · monotherapy —2 mg NCT04706793 · Phase 3 · monotherapy 5.2% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 0%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 4.5%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 6%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 7.7%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence | 2.9%60 mg once dailye NCT05156125 · Phase 2 · monotherapy show 6 more results—60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy —60 mg once daily NCT05156125 · Phase 2 · monotherapy 1.4%30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Serious AEs | 6.9%2 mge NCT03945188 · Phase 3 · monotherapy show 8 more results2.5%2 mg NCT03996369 · Phase 3 · monotherapy 3.6%2 mg NCT04706793 · Phase 3 · monotherapy 6.5% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 0%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 6.3%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 0%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 5.8%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence | —60 mg once dailye NCT05156125 · Phase 2 · monotherapy show 6 more results4.3%60 mg once daily NCT05156125 · Phase 2 · monotherapy 0%60 mg once daily NCT05156125 · Phase 2 · monotherapy 4.2%60 mg once daily NCT05156125 · Phase 2 · monotherapy —30 mg once daily NCT05156125 · Phase 2 · monotherapy 2.7%30 mg once daily NCT05156125 · Phase 2 · monotherapy 5.4%30 mg once daily NCT05156125 · Phase 2 · monotherapy |
| Most frequent reported AEs | 2 mge anaemia 8.3% (placebo 9.7%) headache 8.3% (placebo 4.9%) covid-19 6.6% (placebo 5.6%) NCT03945188 · Phase 3 · monotherapy show 8 more results2 mg anaemia 5.9% (placebo 6.9%) headache 4.6% (placebo 1.7%) nausea 4.2% (placebo 1.7%) NCT03996369 · Phase 3 · monotherapy 2 mg headache 14.3% (placebo 14.3%) malaise 10.7% (placebo 0%) pyrexia 10.7% (placebo 14.3%) NCT04706793 · Phase 3 · monotherapy colitis ulcerative 12.3% (placebo 10.1%) covid-19 9.7% (placebo 8.9%) alanine aminotransferase increased 8.4% (placebo 1.3%) NCT04607837 · Phase 2 · registry result, not featured evidence 2 mg alanine aminotransferase increased 5.3% (placebo 0%) back pain 5.3% (placebo 0%) blood creatine phosphokinase increased 5.3% (placebo 0%) NCT05061446 · Phase 2 · registry result, not featured evidence 1 mg stomatitis 11.8% (placebo 0%) anaemia 5.9% (placebo 0%) cataract 5.9% (placebo 0%) NCT05061446 · Phase 2 · registry result, not featured evidence 2 mg colitis ulcerative 14.3% (placebo 16.7%) anaemia 8.9% (placebo 0%) gamma-glutamyltransferase increased 8.9% (placebo 0%) NCT02536404 · Phase 2 · registry result, not featured evidence 2 mg anaemia 6% (placebo 3.7%) headache 6% (placebo 1.9%) colitis ulcerative 4% (placebo 1.9%) NCT02447302 · Phase 2 · registry result, not featured evidence 1 mg upper respiratory tract infection 7.7% (placebo 3.7%) colitis ulcerative 5.8% (placebo 1.9%) anaemia 3.8% (placebo 3.7%) NCT02447302 · Phase 2 · registry result, not featured evidence | 60 mg once dailye upper respiratory tract infection 8.6% (placebo 1.4%) headache 5.7% (placebo 2.9%) anaemia 2.9% (placebo 8.6%) NCT05156125 · Phase 2 · monotherapy show 4 more results60 mg once daily alanine aminotransferase increased 6.1% (placebo 1.4%) aspartate animotransferase increased 6.1% (placebo 0%) gamma-glutamyltransferase increased 6.1% (placebo 1.4%) NCT05156125 · Phase 2 · monotherapy 60 mg once daily lymphopenia 28.9% (placebo 0%) nasopharyngitis 7.4% (placebo 4.3%) upper respiratory tract infection 6.3% (placebo 1.4%) NCT05156125 · Phase 2 · monotherapy 30 mg once daily headache 6.8% (placebo 2.9%) anaemia 5.5% (placebo 8.6%) lymphopenia 1.4% (placebo 0%) NCT05156125 · Phase 2 · monotherapy 30 mg once daily gamma-glutamyltransferase increased 10.8% (placebo 1.4%) alanine aminotransferase increased 5.4% (placebo 1.4%) arthralgia 5.4% (placebo 0%) NCT05156125 · Phase 2 · monotherapy |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cAssessment timepoints differ: 16 weeks versus 13 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
etrasimod
show 9 more results
show 5 more results
show 6 more results
show 2 more results
show 8 more results
show 4 more results
show 16 more results
show 10 more results
show 14 more results
+ 9 further endpoints in the CSV export.
tamuzimod
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: etrasimod's landscape · tamuzimod's landscape